R. Gary Lane, II MD
Welcome,         Profile    Billing    Logout  
 9 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Smith, Stephen
COMFORT, NCT05750589: Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

Recruiting
3
240
US
IRX-101, Providone-Iodine
iRenix Medical, Inc.
Retinal Disease
06/24
08/24
BRUIN-MCL-321, NCT04662255: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
NCT04987294: Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

Terminated
2a
19
US
ALLN-346, Engineered urate oxidase, Placebo, Matching placebo capsule
Allena Pharmaceuticals
Hyperuricemia, Gout, Chronic Kidney Diseases
09/22
09/22
NCT03401853: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, rituximab biosimilar TQB2303, rituximab-abbs, Truxima, Rituximab Biosimilar SIBP-02, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
University of Washington, Merck Sharp & Dohme LLC
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
12/23
12/25
RELIEF, NCT05747430: SteRilizing Eye SoLution to ImprovE Patient ComFort

Recruiting
2
75
US
IRX-101, Providone-Iodine
iRenix Medical, Inc.
Retinal Disease
06/24
08/24
SIDNEY, NCT04669171 / 2020-003999-40: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Recruiting
1/2
60
Europe, US
EO2463, lenalidomide, Revlimid, rituximab, MabThera
Enterome
Follicular Lymphoma, Marginal Zone Lymphoma
06/25
09/29
NCT05225584: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Recruiting
1
120
US
KT-333
Kymera Therapeutics, Inc.
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors
02/25
03/25
Angueira, Francisco
COMFORT, NCT05750589: Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

Recruiting
3
240
US
IRX-101, Providone-Iodine
iRenix Medical, Inc.
Retinal Disease
06/24
08/24

Download Options